Patents Assigned to BliNK BIOMEDICAL
  • CD96-BINDING AGENTS AS IMMUNOMODULATORS
    Publication number: 20230192845
    Abstract: Provided is a CD96-binding agent, wherein the agent is capable of stimulating activation and/or proliferation of T cells upon binding to CD96. Also provided are isolated nucleic acids and cells that produce the agent and uses thereof.
    Type: Application
    Filed: August 10, 2018
    Publication date: June 22, 2023
    Applicants: BLINK BIOMEDICAL SAS, TALIX THERAPEUTICS NV
    Inventors: Florence Renart-Depontieu, Sachiko Takami, Germain Margall-Ducos, Nicola Beltraminel-Li, Pierre Garrone, Anne Rogel, Aymen Al-Shamkhani, Xavier Preville
  • NOVEL NICOTINE-BINDING ANTIBODIES
    Publication number: 20230089068
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Application
    Filed: August 12, 2022
    Publication date: March 23, 2023
    Applicants: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. KALNIK, Thomas THISTED, Nicola BELTRAMINELLI, Stéphanie FALLOT, Zuzana BIESOVA, Steve FULLER, Mark G. LeSAGE, Paul PENTEL
  • Nicotine-binding antibodies
    Patent number: 11440970
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: September 13, 2022
    Assignees: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. Kalnik, Thomas Thisted, Nicola Beltraminelli, Stéphanie Fallot, Zuzana Biesova, Steve Fuller, Mark G. Lesage, Paul Pentel
  • NOVEL NICOTINE-BINDING ANTIBODIES
    Publication number: 20200377616
    Abstract: Described are novel nicotine-binding antibodies and methods of using them for treating nicotine addiction and/or facilitating smoking cessation, or for treating nicotine overdose or nicotine poisoning.
    Type: Application
    Filed: August 14, 2018
    Publication date: December 3, 2020
    Applicants: ANTIDOTE THERAPEUTICS, INC., BliNK BIOMEDICAL, Hennepin Healthcare Research Institute
    Inventors: Matthew W. KALNIK, Thomas THISTED, Nicola BELTRAMINELLI, Stéphanie FALLOT, Zuzana BIESOVA, Steve FULLER, Mark G. LESAGE, Paul PENTEL